Literature DB >> 7540388

Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin.

J W Miller1, A W Walsh, M Kramer, T Hasan, N Michaud, T J Flotte, R Haimovici, E S Gragoudas.   

Abstract

OBJECTIVE: To investigate photodynamic therapy of experimental choroidal neovascularization using benzoporphyrin derivative monoacid (Verteporfin).
METHODS: Photodynamic therapy using benzoporphyrin derivative monoacid was investigated in cynomolgus monkeys. Following intravenous injection of benzoporphyrin derivative monoacid (1 to 2 mg/kg) complexed with low-density lipoprotein, the eyes were irradiated with 692-nm light at a fluence of 50 to 150 J/cm2 and irradiance of 150 to 600 mW/cm2. Choroidal neovascularization was documented before photodynamic therapy and closure was demonstrated by fundus photography, fluorescein angiography, and light and electron microscopic examination.
RESULTS: Following photodynamic therapy, vessels within choroidal neovascularization were occluded, and there was damage to the choroidal neovascularization endothelium and the subjacent choriocapillaris. Damage to the retinal pigment epithelium and photoreceptors was also observed.
CONCLUSION: Photodynamic therapy with lipoprotein-delivered benzoporphyrin derivative monoacid was effective in this animal model of choroidal neovascularization and may be a promising, potentially selective, therapy for choroidal neovascularization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540388     DOI: 10.1001/archopht.1995.01100060136048

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  31 in total

Review 1.  Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.

Authors:  G Soubrane; N M Bressler
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Photodynamic therapy for choroidal neovascularization. The Jules Gonin Lecture, Montreux, Switzerland, 1 September 2002.

Authors:  Joan W Miller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-03-11       Impact factor: 3.117

3.  Equilibrium and kinetic studies of the interactions of a porphyrin with low-density lipoproteins.

Authors:  Stéphanie Bonneau; Christine Vever-Bizet; Patrice Morlière; Jean-Claude Mazière; Daniel Brault
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

Review 4.  Cholesterol oxidation in the retina: implications of 7KCh formation in chronic inflammation and age-related macular degeneration.

Authors:  Ignacio R Rodríguez; Ignacio M Larrayoz
Journal:  J Lipid Res       Date:  2010-06-21       Impact factor: 5.922

Review 5.  The ins and outs of cholesterol in the vertebrate retina.

Authors:  Steven J Fliesler; Lionel Bretillon
Journal:  J Lipid Res       Date:  2010-09-22       Impact factor: 5.922

6.  Concentric retinal pigment epithelium atrophy after a single photodynamic therapy.

Authors:  Joachim Wachtlin; Tim Behme; Heinrich Heimann; Ulrich Kellner; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-05-07       Impact factor: 3.117

7.  [Photodynamic therapy with verteporfin for uveal melanoma].

Authors:  J Wachtlin; N E Bechrakis; M H Foerster
Journal:  Ophthalmologe       Date:  2005-03       Impact factor: 1.059

8.  Combined photodynamic therapy and intravitreal bevacizumab injection for the treatment of adult Coats' disease: a case report.

Authors:  Jongshin Kim; Kyu Hyung Park; Se Joon Woo
Journal:  Korean J Ophthalmol       Date:  2010-11-23

9.  Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration.

Authors:  Eric Chen; David M Brown; Tien P Wong; Matthew S Benz; Eric Kegley; Joel Cox; Richard H Fish; Rosa Y Kim
Journal:  Clin Ophthalmol       Date:  2010-10-05

10.  Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).

Authors:  Joan W Miller
Journal:  Trans Am Ophthalmol Soc       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.